Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease
Diabetes, Obesity and Metabolism Apr 06, 2020
Saeed MI, Eklöf J, Achir I, et al. - Using Danish health databases, researchers analyzed data from patients with chronic obstructive pulmonary disease (COPD) between 1 January 2010 and 31 December 2017, in this nationwide observational cohort analysis, to assess the risk of T2D onset related to accumulated inhaled corticosteroids (ICS) dose during the previous year in these patients. A rise in the risk of T2D was revealed, in the propensity‐matched Cox model (N = 33,466), which was shown to progress with increasing accumulated ICS dose, vs no ICS use. Overall, findings revealed a link between ICS use and a moderate dose‐dependent rise in the occurrence of T2D among patients with COPD.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries